Tarsus Pharmaceuticals, Inc. TARS Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease right-of-use assets in other assets of $9.99M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets increased by 2443.0% year-over-year, from $393K to $9.99M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease right-of-use assets in other assets has grown at a 71.1% compound annual growth rate (CAGR), from $688K to $10.08M.